Press Releases

10.25.22
OpGen Subsidiary Curetis and BioVersys Sign Collaboration Agreement for Clinical Trial Support
10.03.22
OpGen Announces Closing of $3.38 Million Registered Direct Offering
10.03.22
OpGen Announces Successful Completion of Clinical Trial Enrollment for Unyvero Urinary Tract Infection Panel
09.30.22
OpGen Announces $3.38 Million Registered Direct Offering
09.20.22
OpGen Subsidiary Curetis and FIND Sign R&D Collaboration Agreement for Unyvero A30 RQ Platform
09.06.22
OpGen Announces Participation at the H.C. Wainwright 24th Annual Global Investment Conference
08.31.22
Nasdaq Grants OpGen 180-Day Extension to Meet Minimum Bid Price Requirement
08.25.22
OpGen Launches Ares Sequencing Services in the U.S. from its Rockville, Maryland Laboratory
08.11.22
OpGen Reports Second Quarter 2022 Financial Results and Provides Business Update
07.28.22
OpGen to Provide Business Update and Financial Results for the Second Quarter 2022 on August 11th at 4:30 p.m. Eastern Time